drugset / Trial / NCT03101709
The Safety and Efficacy of CART-19 Cells in Relapse and Refractory Patients With CD19+ B-cell Lymphoma
Phase 1
Unknown
30 enrolled
Henan Cancer Hospital
The Beijing Pregene Science and Technology Company, Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a clinical study to observe the safety and feasibility of chimeric antigen receptor 19 (CART-19) cells in relapsed and refractory patients with CD19+ B cell lymphoma.
Timeline
- Start
- 2016-08
- Primary completion
- 2018-07
- Completion
- 2019-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tisagenlecleucel | Cell therapy | — | — |
| Background | Cyclophosphamide | Other / unclassified | 800 mg/m2 | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | 1000 mg/m2 | Intravenous |
| Background | Fludarabine | Small molecule | 25 mg/m2 | Intravenous |